Advanced

Molecular insights on basal-like breast cancer.

Dominguez, Mev LU ; da Silva, Sabrina Daniela; Privat, Maud; Alaoui-Jamali, Moulay and Bignon, Yves-Jean (2012) In Breast Cancer Research and Treatment 134(1). p.21-30
Abstract
Molecular classification of breast cancer (BC) identified diverse subgroups that encompass distinct biological behavior and clinical implications, in particular in relation to prognosis, spread, and incidence of recurrence. Basal-like breast cancers (BLBC) compose up to 15% of BC and are characterized by lack of estrogen receptor (ER), progesterone receptor (PR), and HER-2 amplification with expression of basal cytokeratins 5/6, 14, 17, epidermal growth factor receptor (EGFR), and/or c-KIT. There is an overlap in definition between triple-negative BC and BLBC due to the triple-negative profile of BLBC. Also, most BRCA1-associated BCs are BLBC, triple negative, and express basal cytokeratins (5/6, 14, 17) and EGFR. There is a link between... (More)
Molecular classification of breast cancer (BC) identified diverse subgroups that encompass distinct biological behavior and clinical implications, in particular in relation to prognosis, spread, and incidence of recurrence. Basal-like breast cancers (BLBC) compose up to 15% of BC and are characterized by lack of estrogen receptor (ER), progesterone receptor (PR), and HER-2 amplification with expression of basal cytokeratins 5/6, 14, 17, epidermal growth factor receptor (EGFR), and/or c-KIT. There is an overlap in definition between triple-negative BC and BLBC due to the triple-negative profile of BLBC. Also, most BRCA1-associated BCs are BLBC, triple negative, and express basal cytokeratins (5/6, 14, 17) and EGFR. There is a link between sporadic BLBC (occurring in women without germline BRCA1 mutations) with dysfunction of the BRCA1 pathway. Despite the molecular and clinical similarities, these subtypes respond differently to neoadjuvant therapy. BLBCs are associated with an aggressive phenotype, high histological grade, poor clinical behavior, and high rates of recurrences and/or metastasis. Their molecular features render these tumors especially refractory to anti-hormonal-based therapies and the overall prognosis of this subset remains poor. In this article, the molecular profile, genomic, and epigenetic characteristics as well as BRCA1 pathway dysfunction, clinicopathological behavior, and therapeutic options in BLBC are presented, with emphasis on the discordant findings in current literature. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Basal-like breast cancer, Breast cancer, Triple negative, BRCA1, Transcriptional profiling, Prognosis
in
Breast Cancer Research and Treatment
volume
134
issue
1
pages
21 - 30
publisher
Springer
external identifiers
  • wos:000306437500003
  • pmid:22234518
  • scopus:84863982081
ISSN
1573-7217
DOI
10.1007/s10549-011-1934-z
language
English
LU publication?
yes
id
d66ac9d9-da8f-4fc2-b183-5519bd7e1987 (old id 2336565)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22234518?dopt=Abstract
date added to LUP
2012-02-01 20:17:29
date last changed
2017-09-03 04:22:11
@article{d66ac9d9-da8f-4fc2-b183-5519bd7e1987,
  abstract     = {Molecular classification of breast cancer (BC) identified diverse subgroups that encompass distinct biological behavior and clinical implications, in particular in relation to prognosis, spread, and incidence of recurrence. Basal-like breast cancers (BLBC) compose up to 15% of BC and are characterized by lack of estrogen receptor (ER), progesterone receptor (PR), and HER-2 amplification with expression of basal cytokeratins 5/6, 14, 17, epidermal growth factor receptor (EGFR), and/or c-KIT. There is an overlap in definition between triple-negative BC and BLBC due to the triple-negative profile of BLBC. Also, most BRCA1-associated BCs are BLBC, triple negative, and express basal cytokeratins (5/6, 14, 17) and EGFR. There is a link between sporadic BLBC (occurring in women without germline BRCA1 mutations) with dysfunction of the BRCA1 pathway. Despite the molecular and clinical similarities, these subtypes respond differently to neoadjuvant therapy. BLBCs are associated with an aggressive phenotype, high histological grade, poor clinical behavior, and high rates of recurrences and/or metastasis. Their molecular features render these tumors especially refractory to anti-hormonal-based therapies and the overall prognosis of this subset remains poor. In this article, the molecular profile, genomic, and epigenetic characteristics as well as BRCA1 pathway dysfunction, clinicopathological behavior, and therapeutic options in BLBC are presented, with emphasis on the discordant findings in current literature.},
  author       = {Dominguez, Mev and da Silva, Sabrina Daniela and Privat, Maud and Alaoui-Jamali, Moulay and Bignon, Yves-Jean},
  issn         = {1573-7217},
  keyword      = {Basal-like breast cancer,Breast cancer,Triple negative,BRCA1,Transcriptional profiling,Prognosis},
  language     = {eng},
  number       = {1},
  pages        = {21--30},
  publisher    = {Springer},
  series       = {Breast Cancer Research and Treatment},
  title        = {Molecular insights on basal-like breast cancer.},
  url          = {http://dx.doi.org/10.1007/s10549-011-1934-z},
  volume       = {134},
  year         = {2012},
}